Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.

Angelo Valerio Marzano Giovanni Genovese Giovanni CasazzaC MoltrasioP DapavoG MicaliR SirnaPaolo Gisondi Annalisa PatriziV DiniD BianchiniL BianchiLuca Fania Francesca PrignanoA OffidaniLaura AtzoriV BettoliS P CannavòMarina VenturiniM R BongiornoA CostanzoG FabbrociniK Peris

Published in: The British journal of dermatology (2020)

Inverse correlation between therapeutic delay and clinical response was found, supporting early adalimumab use and providing evidence for a 'window of opportunity' in HS treatment. Adalimumab efficacy and safety were confirmed, along with patients' QoL improvement. Immunosuppressants could negatively influence the response to adalimumab inducing a switch to non-TNF-α-driven pathways.

Keyphrases

hidradenitis suppurativa
rheumatoid arthritis
juvenile idiopathic arthritis
newly diagnosed
end stage renal disease
ulcerative colitis
ejection fraction
chronic kidney disease
prognostic factors
randomized controlled trial
disease activity
cross sectional
patient reported outcomes